GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pasithea Therapeutics Corp (NAS:KTTA) » Definitions » FCF Yield %

KTTA (Pasithea Therapeutics) FCF Yield % : -419.28 (As of Dec. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pasithea Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Pasithea Therapeutics's Trailing 12-Month Free Cash Flow is $-14.18 Mil, and Market Cap is $3.38 Mil. Therefore, Pasithea Therapeutics's FCF Yield % for today is -419.28%.

The historical rank and industry rank for Pasithea Therapeutics's FCF Yield % or its related term are showing as below:

KTTA' s FCF Yield % Range Over the Past 10 Years
Min: -419.28   Med: -83.91   Max: -7.79
Current: -419.28


During the past 4 years, the highest FCF Yield % of Pasithea Therapeutics was -7.79%. The lowest was -419.28%. And the median was -83.91%.

KTTA's FCF Yield % is ranked worse than
96.48% of 1507 companies
in the Biotechnology industry
Industry Median: -12.65 vs KTTA: -419.28

Pasithea Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.


Pasithea Therapeutics FCF Yield % Historical Data

The historical data trend for Pasithea Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pasithea Therapeutics FCF Yield % Chart

Pasithea Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
FCF Yield %
- -7.85 -71.82 -166.69

Pasithea Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -129.10 -140.12 -228.51 -305.77 -220.36

Competitive Comparison of Pasithea Therapeutics's FCF Yield %

For the Biotechnology subindustry, Pasithea Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pasithea Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Pasithea Therapeutics's FCF Yield % falls into.



Pasithea Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Pasithea Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-12.848 / 7.707692
=-166.69%

Pasithea Therapeutics's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-3.12 * 4 / 5.6634122
=-220.36%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pasithea Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Pasithea Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Pasithea Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pasithea Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
Executives
Graeme Martin Currie officer: Chief Development Officer 51 BARBAREE WAY, TIBURON CA 94920
Lawrence Steinman director 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Bradford Manning 10 percent owner C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Paul B Manning 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Tiger Lily Capital, Llc 10 percent owner C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Pd Joint Holdings, Llc Series 2016-a 10 percent owner C/O TIGER LILY CAPITAL LLC, 200 GARRETT STREET, SUITE O, CHARLOTTESVILLE VA 22902
Elderhill Corp other: Member of 10% owner group C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T IN5
Concord Ip2 Ltd. other: Member of 10% owner group C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
David Delaney other: Member of 10% owner group C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
Eric Shahinian other: Member of 10% owner group 350 PARK AVE, 13TH FL, NEW YORK NY 10022
Alfred J Novak director 325 NE 6TH ST, BOCA RATON FL 33432
Camac Partners, Llc other: Member of 10% owner group 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Capital, Llc other: Member of 10% owner group 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Fund, Lp other: Member of 10% owner group CAMAC CAPITAL, LLC, 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Leonite Capital Llc other: Member of 10% owner group 1 HILLCREST CENTER DR., SUITE 232, SPRING VALLEY NY 10977